Camrelizumab
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | DRUG-CAMRELIZUMAB |
|---|---|
| Art | Arzneimittel |
| Aliase | AiRuiKaSHR-1210Камрелізумаб |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Erkrankungen | DIS-NPC |
| Quellen | SRC-CAPTAIN-1ST-YANG-2021 |
Drug Facts
| Klasse | Anti-PD-1 humanisierter IgG4 monoklonaler Antikörper (Immun-Checkpoint-Inhibitor) |
|---|---|
| Verfahren | Humanized IgG4 monoclonal antibody binding PD-1 on activated T cells, blocking PD-1/PD-L1 and PD-1/PD-L2 interactions and restoring cytotoxic T-cell antitumor activity. Same general anti-PD-1 mechanistic class as pembrolizumab, nivolumab, and toripalimab. Studied specifically in recurrent/metastatic nasopharyngeal carcinoma (CAPTAIN-1st) combined with gemcitabine + cisplatin, as well as in multiple other Chinese-registered indications (hepatocellular carcinoma, NSCLC, esophageal SCC, classical Hodgkin lymphoma). |
| Typische Dosierung | Per the CAPTAIN-1st trial protocol: camrelizumab 200 mg IV every 3 weeks, combined with gemcitabine + cisplatin (GP) for up to 6 cycles, followed by camrelizumab monotherapy (200 mg IV q3w) until disease progression, unacceptable toxicity, or up to 2 years total. STUB — dosing drafted from trial-protocol recall; pending Clinical Co-Lead confirmation against the primary source. |
| Ukraine registriert | Falsch |
| NSZU erstattet | Falsch |
Anmerkungen
STUB — draft entity pending Clinical Co-Lead sign-off (CHARTER §6.1; currently dev-mode-exempted). Anti-PD-1 backbone alternative for NPC metastatic 1L combination per CAPTAIN-1st (Yang Y et al., Lancet Oncol 2021): camrelizumab + gemcitabine + cisplatin significantly improved PFS vs chemo alone in treatment-naive recurrent/metastatic NPC. NOT FDA-approved (China/NMPA-approved only) — distinguishes it from toripalimab (DRUG-TORIPALIMAB), the FDA-approved alternative for the identical clinical scenario. Reuse this entity rather than duplicate. RCCEP is a genuinely distinctive camrelizumab-class AE not shared with pembrolizumab/nivolumab/toripalimab — worth flagging for patient counseling.
Verwendet von
Arzneimittel
DRUG-TORIPALIMAB- Toripalimab
Therapieschema
REG-NPC-GC-CAMRELIZUMAB- Camrelizumab + gemcitabine + cisplatin (CAPTAIN-1st) — 1L rezidivierende/metastatische Nasopharyn...